drugset / Trial / NCT00396253

A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters

NCT00396253

Phase 3 Completed 223 enrolled Genentech, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This was a Phase III, open-label study conducted at 44 centers in the United States, Canada, and Puerto Rico. 223 subjects who required hemodialysis (HD) and had a dysfunctional HD catheter were enrolled in the study.

Timeline

Start
2006-11
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenecteplase Protein / enzyme biologic 2 ml Other
Subject Tenecteplase Protein / enzyme biologic 2 mg Other

Indications

No indication recorded.